Vimta Labs Q4 FY26 Earnings Call — Analysis (NSE: VIMTALABS)
Vimta Labs reports Q4FY26 revenue of ₹112 Cr (+16.6% YoY), EBITDA margin of 37.6%, and enters biologics contract research; targets 20-25% CAGR and ₹500 Cr annualized run-rate.
The take
FY26 Total income ₹416.3 Cr ( +19.5% YoY ) . New guidance — revenue cagr over next 3-4 years 20-25% . New story: Biologics entry as new growth vector .
Results
Revenue ₹112 Cr +16.6% YoY; EBITDA ₹42.1 Cr +21.5% YoY; PAT ₹21.1 Cr +15.2% YoY; EBITDA margin 37.6%.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total income | ₹112 Cr | +16.6% | yoy · Q4FY26 |
| EBITDA | ₹42.1 Cr | +21.5% | yoy · Q4FY26 |
| PAT | ₹21.1 Cr | +15.2% | yoy · Q4FY26 |
| EBITDA margin | 37.6% | none · Q4FY26 | |
| PAT margin | 18.9% | none · Q4FY26 | |
| Total income | ₹416.3 Cr | +19.5% | yoy · FY26 |
| EBITDA | ₹148.9 Cr | +18.0% | yoy · FY26 |
| PAT | ₹77.5 Cr | +16.1% | yoy · FY26 |
| EBITDA margin | 35.8% | none · FY26 | |
| PAT margin | 18.6% | none · FY26 | |
| Cash & equivalents | ₹65 Cr | point_in_time · FY26 · as of Mar-26 |
Guidance
Management targets 20-25% revenue CAGR over next 3-4 years, aims to reach ₹500 Cr annualized run-rate in FY27, and expects to sustain EBITDA margins around 35% with minor corrections.
What management committed to
- Vimta Labs targets a 20-25% revenue CAGR over the next three to four years. — 20-25%, next three to four years
- Vimta Labs aims to achieve an annualized revenue run-rate of ₹500 Cr. — ₹500 Cr, FY27
- Vimta Labs expects to sustain EBITDA margins around 35%, with a possible correction of 1-2% due to input cost and manpower pressures. — around 35% with possible 1-2% correction, FY27
- Vimta Labs expects to onboard at least a few good clients in the biologics contract research business in FY27. — a few good clients, FY27
- Utilization of [the new facility] will pick up gradually, with a little more in FY27, more in FY28, and further in FY29. — FY27, FY28, FY29
- With leadership challenges resolved, [the electronics and electrical testing segment] is expected to see strong movement. — FY27
Key themes
Biologics entry, margin resilience, export push
How the narrative shifted
- Biologics entry as new growth vector: Management positions biologics CRO as a long-term strategic bet, with FY27 as a year of learning, execution, and credibility building.
- Resilient core testing demand: Pharma and food testing continue to drive steady growth, underpinned by outsourcing trends, tightening quality norms, and essential nature of testing.
- Export expansion and US subsidiary: Setting up a US subsidiary to be closer to customers and build confidence, with 38% export share in Q4 reflecting increasing overseas traction.
- Margin sustainability amid cost pressures: Management expects to maintain industry-leading margins around 35% with minor fluctuations, offsetting input cost and manpower increases through topline growth.
- Capacity ramp and infrastructure leverage: New facility built for multi-year growth; utilization will ramp gradually, ensuring headroom for expansion without immediate capex pressure.
- Geopolitical uncertainties as headwinds: War and tariff disruptions impact input costs and client sentiment, with a wait-and-watch approach; recent tariff reversals are hopeful.
- Electronics testing turnaround: Leadership issues in electronics testing have been resolved, and the segment is expected to regain momentum.
Operational commentary
- Biologics contract research and development services launched; infrastructure, systems, and people ready; projects under discussion with clients from Europe, India, and US, expecting to onboard first clients in FY27.
- Pharma and food testing drove Q4 revenue growth; food testing had a strong quarter but saw a temporary disruption in the last fortnight of March due to war-related supply chain impacts.
- Electronics and electrical testing segment had a slow year due to leadership challenges on the technical and BD sides; those issues are now resolved, and the outlook for the segment is positive.
- Export revenue contributed 38% of Q4 revenue; a US subsidiary has been approved to be closer to customers and build confidence, with no near-term tariff advantage expected.
- New facility capacity utilization will ramp up gradually over the next few years; the facility was built to accommodate growth for the next 4-5 years.
- Balance sheet remains net debt-free with ~₹65 Cr in cash and equivalents; management has no immediate plans for capital deployment, acquisitions, or new service lines.
- Environmental testing has been scaled down to post-project monitoring only, and is not a focus area for growth.
Analyst Q&A
Q. Could you provide the margin profile of each of your four verticals?
We don't differentiate the margins between our service lines. It's all treated as one service, so that information is not available.
Q. Have you signed clients yet on the biosimilar/biosimilar side?
We have good inquiries and we will be closing them soon. We have good traction from Europe, India, a couple from US as well. We're just finalizing the product and the modality.
Research and educational content only. Not investment advice.